-
41
Natalizumab in the treatment of multiple sclerosis. Experience of the Moscow Multiple Sclerosis Center (MMSC)
Published 2014-12-01Subjects: Get full text
Article -
42
-
43
Fingolimod for the treatment of remitting multiple sclerosis: experience of the Moscow Multiple Sclerosis Center (MMSC)
Published 2014-12-01Subjects: Get full text
Article -
44
Intrathecal, Not Systemic Inflammation Is Correlated With Multiple Sclerosis Severity, Especially in Progressive Multiple Sclerosis
Published 2019-11-01Subjects: “…multiple sclerosis…”
Get full text
Article -
45
Neuroimaging to monitor worsening of multiple sclerosis: advances supported by the grant for multiple sclerosis innovation
Published 2023-12-01Subjects: “…multiple sclerosis diagnostic imaging…”
Get full text
Article -
46
Novel SNARE Complex Polymorphisms Associated with Multiple Sclerosis: Signs of Synaptopathy in Multiple Sclerosis
Published 2019-05-01Subjects: “…Multiple sclerosis…”
Get full text
Article -
47
Multiple sclerosis and pregnancy. Impact of multiple sclerosis disease-modifying therapy on the health of newborns
Published 2021-02-01“…Due to the high prevalence of multiple sclerosis (MS) among women of reproductive age, special attention is paid to the management of pregnancy in them. …”
Get full text
Article -
48
B cells in multiple sclerosis
Published 2017-01-01Subjects: “…multiple sclerosis…”
Get full text
Article -
49
Activation of Necroptosis in Multiple Sclerosis
Published 2015-03-01“…Multiple sclerosis (MS), a common neurodegenerative disease of the CNS, is characterized by the loss of oligodendrocytes and demyelination. …”
Get full text
Article -
50
-
51
-
52
Multiple sclerosis and dizziness in the elderly
Published 2019-09-01Subjects: “…multiple sclerosis…”
Get full text
Article -
53
Alemtuzumab for the treatment of multiple sclerosis
Published 2015-03-01“…Mark D Willis, Neil P Robertson Institute of Psychological Medicine and Clinical Neuroscience, Cardiff University, University Hospital of Wales, Heath Park, Cardiff, UK Abstract: Alemtuzumab is an anti-CD52 monoclonal antibody, recently approved for the treatment of active, relapsing multiple sclerosis (MS). Administration of alemtuzumab causes a rapid and dramatic reduction in circulating lymphocytes, with a predictable subsequent pattern of immune reconstitution. …”
Get full text
Article -
54
-
55
The symptomatic management of multiple sclerosis
Published 2009-01-01Subjects: Get full text
Article -
56
Multiple sclerosis and herpesvirus interaction
Published 2013-09-01“…Multiple sclerosis is the most common autoimmune inflammatory demyelinating disease of the central nervous system, and its etiology is believed to have both genetic and environmental components. …”
Get full text
Article -
57
Late onset multiple sclerosis
Published 2011-01-01“…Introduction: Late onset multiple sclerosis (LOMS) is an unusual entity, poorly characterized and difficult to diagnose. …”
Get full text
Article -
58
Digital Biomarkers in Multiple Sclerosis
Published 2021-11-01Subjects: “…multiple sclerosis…”
Get full text
Article -
59
Symptomatic management in multiple sclerosis
Published 2015-01-01Subjects: “…Multiple sclerosis…”
Get full text
Article -
60
Multiple Sclerosis In South India
Published 2005-01-01“…We studied the clinical, imaging, electrophysiological and laboratory features of 68 patients with multiple sclerosis (MS), diagnosed between 19We studied the clinical, imaging, electrophysiological and laboratory features of 68 patients with multiple sclerosis (MS), diagnosed between 1987 and 1997 in a neurological institute in South India. …”
Get full text
Article